Mostrar registro simples

dc.contributor.authorCecconello, Daiane Kellerpt_BR
dc.contributor.authorRechenmacher, Cilianapt_BR
dc.contributor.authorWerlang, Isabel Cristina Ribaspt_BR
dc.contributor.authorZenatti, Priscila Pinipt_BR
dc.contributor.authorYunes, José Andréspt_BR
dc.contributor.authorAlegretti, Ana Paulapt_BR
dc.contributor.authorKaminsky, Claudia Lanverspt_BR
dc.contributor.authorDaudt, Liane Estevespt_BR
dc.contributor.authorMichalowski, Mariana Bohnspt_BR
dc.date.accessioned2022-01-27T04:32:20Zpt_BR
dc.date.issued2020pt_BR
dc.identifier.issn2045-2322pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/234504pt_BR
dc.description.abstractAcute lymphoid leukemia is a childhood cancer that in high‑income countries has event‑free survival rates of 80% and global survival rates of 90%. In Brazil these rates are under 70%. This difference may be due to the implementation of supportive care, including the assessment of asparaginase (ASNase) activity. ASNase may cause hypersensitivity reactions and silent drug inactivation. For this reason, ASNase activity monitoring is an essential tool to ensure an effective treatment. Our aim was to implement an ASNase activity measurement technique at a hospital setting. samples from children who were given Escherichia coli‑derived ASNase were collected. The results of the analyses conducted in our laboratory Hospital de Clínicas de Porto Alegre were compared to those of two institutions: Centro Infantil Boldrini and University of Munster. 262 samples were assessed. The results of the first analyses were compared with those obtained at Centro Infantil Boldrini and showed an ICC of 0.954. Thirty samples were sent to the University of Munster and presented an ICC was 0.960. Our results, when compared to those of national and international centers, showed an excellent agreement. The study was able to implement an ASNase activity test to monitor the treatment.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofScientific reports. London. Vol. 10 (2020), 21481, [6 p.]pt_BR
dc.rightsOpen Accessen
dc.subjectLeucemia-linfoma linfoblástico de células precursoraspt_BR
dc.subjectAsparaginasept_BR
dc.subjectAvaliação de resultados da assistência ao pacientept_BR
dc.titleImplementation of the asparaginase activity assessment technique for clinical use : experience of a Brazilian Centerpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001135911pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples